The Swiss-based company is currently developing a novel generation of drugs addressing serious conditions affecting women’s reproductive health and compromising pregnancy from conception to birth.

Its lead programs target the underserved problems of endometriosis, infertility and preterm labor affecting more and more women worldwide.